10-Q Filing

REGENERON PHARMACEUTICALS, INC. CIK: 872589 Q3 2020

Filing Information

Form Type	10-Q
Accession Number	`0001804220-20-000030`
Period End Date	20200930
Filing Date	20201105
Fiscal Year	2020
Fiscal Period	Q3
XBRL Instance	regn-20200930_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 73 Income Statement 88 Cash Flow Statement 62 Stockholders Equity 62

Balance Sheet 73 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred Stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred Stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred Stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred Stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred Stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred Stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred Stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.62B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.38B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.57B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$1.45B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$1.60B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$2.10B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$3.09B	USD	Point-in-time
Accounts receivable - Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$260.60M	USD	Point-in-time
Accounts receivable - Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$460.80M	USD	Point-in-time
Treasury Stock (in shares)	`TreasuryStockShares`	4.86M	shares	Point-in-time
Accounts receivable - other	`AccountsAndNotesReceivableNet`	$486.20M	USD	Point-in-time
Treasury Stock (in shares)	`TreasuryStockShares`	15.74M	shares	Point-in-time
Accounts receivable - other	`AccountsAndNotesReceivableNet`	$425.00M	USD	Point-in-time
Inventories	`InventoryNet`	$1.42B	USD	Point-in-time
Inventories	`InventoryNet`	$1.80B	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$273.70M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$230.60M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$7.69B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$9.10B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$2.88B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$3.26B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$3.14B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.89B	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$824.20M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$804.20M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$168.80M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$144.70M	USD	Point-in-time
Total assets	`Assets`	$14.81B	USD	Point-in-time
Total assets	`Assets`	$16.08B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrentAndNoncurrent`	$443.10M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrentAndNoncurrent`	$418.10M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$1.21B	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$1.30B	USD	Point-in-time
Other liabilities - Sanofi	`OtherLiabilitiesCurrent`	$85.00M	USD	Point-in-time
Other liabilities - Sanofi	`OtherLiabilitiesCurrent`	$96.90M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.34B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.10B	USD	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	$1.98B	USD	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	-	USD	Point-in-time
Finance lease liabilities	`FinanceLeaseLiabilityNoncurrent`	$713.90M	USD	Point-in-time
Finance lease liabilities	`FinanceLeaseLiabilityNoncurrent`	$716.50M	USD	Point-in-time
Other noncurrent liabilities	`OtherLiabilitiesNoncurrent`	$454.00M	USD	Point-in-time
Other noncurrent liabilities	`OtherLiabilitiesNoncurrent`	$317.70M	USD	Point-in-time
Total liabilities	`Liabilities`	$5.96B	USD	Point-in-time
Total liabilities	`Liabilities`	$3.72B	USD	Point-in-time
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	`PreferredStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$4.43B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$6.59B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$9.74B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$7.38B	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$30.80M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$21.10M	USD	Point-in-time
Treasury Stock, at cost; 15,741,824 shares in 2020 and 4,860,123 shares in 2019	`TreasuryStockValue`	$739.90M	USD	Point-in-time
Treasury Stock, at cost; 15,741,824 shares in 2020 and 4,860,123 shares in 2019	`TreasuryStockValue`	$6.24B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$10.50B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$12.13B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.76B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.44B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$10.13B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$8.76B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.06B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$11.09B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$14.81B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$16.08B	USD	Point-in-time

Income Statement 88 line items

Line Item	Tag	Value	Unit	Period
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.69B	USD	3 Qtrs
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.74B	USD	1 Quarter
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$6.07B	USD	3 Qtrs
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$2.29B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.99B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$526.00M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$684.60M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.90B	USD	3 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$1.04B	USD	3 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$326.90M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$890.10M	USD	3 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$304.40M	USD	1 Quarter
Other operating (income) expense, net	`OtherOperatingIncomeExpenseNet`	$135.20M	USD	3 Qtrs
Other operating (income) expense, net	`OtherOperatingIncomeExpenseNet`	$44.60M	USD	1 Quarter
Other operating (income) expense, net	`OtherOperatingIncomeExpenseNet`	$50.70M	USD	1 Quarter
Other operating (income) expense, net	`OtherOperatingIncomeExpenseNet`	$171.10M	USD	3 Qtrs
Total operating expenses	`CostsAndExpenses`	$1.01B	USD	1 Quarter
Total operating expenses	`CostsAndExpenses`	$1.24B	USD	1 Quarter
Total operating expenses	`CostsAndExpenses`	$3.66B	USD	3 Qtrs
Total operating expenses	`CostsAndExpenses`	$3.16B	USD	3 Qtrs
Income from operations	`OperatingIncomeLoss`	$1.05B	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$738.50M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$2.41B	USD	3 Qtrs
Income from operations	`OperatingIncomeLoss`	$1.53B	USD	3 Qtrs
Other (expense) income, net	`OtherNonoperatingIncomeExpense`	$37.80M	USD	1 Quarter
Other (expense) income, net	`OtherNonoperatingIncomeExpense`	$218.30M	USD	3 Qtrs
Other (expense) income, net	`OtherNonoperatingIncomeExpense`	$28.70M	USD	3 Qtrs
Other (expense) income, net	`OtherNonoperatingIncomeExpense`	$-28.50M	USD	1 Quarter
Interest expense	`InterestExpense`	$42.10M	USD	3 Qtrs
Interest expense	`InterestExpense`	$26.30M	USD	1 Quarter
Interest expense	`InterestExpense`	$7.80M	USD	1 Quarter
Interest expense	`InterestExpense`	$23.50M	USD	3 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$176.20M	USD	3 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$30.00M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$-54.80M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$5.20M	USD	3 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$2.59B	USD	3 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.54B	USD	3 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$998.30M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$768.50M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$221.80M	USD	3 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$215.50M	USD	3 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$156.20M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$98.90M	USD	1 Quarter
Net income	`NetIncomeLoss`	$897.30M	USD	1 Quarter
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$2.36B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$669.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$842.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$624.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.32B	USD	3 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$12.12	USD	3 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$21.83	USD	3 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$7.98	USD	1 Quarter
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$6.12	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$11.54	USD	3 Qtrs
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$5.86	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$7.39	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$20.36	USD	3 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	105.50M	shares	1 Quarter
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	109.40M	shares	1 Quarter
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	109.20M	shares	3 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	108.30M	shares	3 Qtrs
Weighted average shares outstanding - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.70M	shares	3 Qtrs
Weighted average shares outstanding - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	113.90M	shares	1 Quarter
Weighted average shares outstanding - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.20M	shares	1 Quarter
Weighted average shares outstanding - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	116.10M	shares	3 Qtrs
Net income	`NetIncomeLoss`	$897.30M	USD	1 Quarter
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$2.36B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$669.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$842.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$624.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.32B	USD	3 Qtrs
Unrealized (loss) gain on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$31.50M	USD	3 Qtrs
Unrealized (loss) gain on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.00M	USD	1 Quarter
Unrealized (loss) gain on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$10.90M	USD	3 Qtrs
Unrealized (loss) gain on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-4.90M	USD	1 Quarter
Unrealized gain (loss) on cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-2.70M	USD	3 Qtrs
Unrealized gain (loss) on cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-1.20M	USD	3 Qtrs
Unrealized gain (loss) on cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$200.00K	USD	1 Quarter
Unrealized gain (loss) on cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-300.00K	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$2.37B	USD	3 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$837.40M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$670.30M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$1.35B	USD	3 Qtrs

Cash Flow Statement 62 line items

Line Item	Tag	Value	Unit	Period
Net income	`NetIncomeLoss`	$897.30M	USD	1 Quarter
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$2.36B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$669.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$842.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$624.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.32B	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$156.00M	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$174.20M	USD	3 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$330.80M	USD	3 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$310.50M	USD	3 Qtrs
Other non-cash items, net	`OtherNoncashIncomeExpense`	$-113.20M	USD	3 Qtrs
Other non-cash items, net	`OtherNoncashIncomeExpense`	$111.30M	USD	3 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$-117.90M	USD	3 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$110.00M	USD	3 Qtrs
Increase in Sanofi, trade, and other accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$1.28B	USD	3 Qtrs
Increase in Sanofi, trade, and other accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$464.50M	USD	3 Qtrs
Increase in inventories	`IncreaseDecreaseInInventories`	$227.20M	USD	3 Qtrs
Increase in inventories	`IncreaseDecreaseInInventories`	$402.40M	USD	3 Qtrs
Decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-24.80M	USD	3 Qtrs
Decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-16.40M	USD	3 Qtrs
Increase in deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$166.80M	USD	3 Qtrs
Increase in deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$112.30M	USD	3 Qtrs
Increase in accounts payable, accrued expenses, and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$80.80M	USD	3 Qtrs
Increase in accounts payable, accrued expenses, and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$328.90M	USD	3 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$318.80M	USD	3 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$-976.90M	USD	3 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.64B	USD	3 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.39B	USD	3 Qtrs
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$2.64B	USD	3 Qtrs
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$2.83B	USD	3 Qtrs
Sales or maturities of marketable and other securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$1.31B	USD	3 Qtrs
Sales or maturities of marketable and other securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$3.33B	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$290.60M	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$453.20M	USD	3 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.82B	USD	3 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$234.40M	USD	3 Qtrs
Proceeds from issuance of long-term debt	`ProceedsFromIssuanceOfLongTermDebt`	-	USD	3 Qtrs
Proceeds from issuance of long-term debt	`ProceedsFromIssuanceOfLongTermDebt`	$1.98B	USD	3 Qtrs
Proceeds from bridge loan facility	`ProceedsFromShortTermDebt`	$1.50B	USD	3 Qtrs
Proceeds from bridge loan facility	`ProceedsFromShortTermDebt`	-	USD	3 Qtrs
Repayment of bridge loan facility	`RepaymentsOfShortTermDebt`	$1.50B	USD	3 Qtrs
Repayment of bridge loan facility	`RepaymentsOfShortTermDebt`	-	USD	3 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$163.50M	USD	3 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$2.47B	USD	3 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$652.50M	USD	3 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$40.50M	USD	3 Qtrs
Repurchases of Common Stock	`PaymentsForRepurchaseOfCommonStock`	$29.40M	USD	3 Qtrs
Repurchases of Common Stock	`PaymentsForRepurchaseOfCommonStock`	$5.47B	USD	3 Qtrs
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-1.67B	USD	3 Qtrs
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$93.60M	USD	3 Qtrs
Net decrease in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-43.70M	USD	3 Qtrs
Net decrease in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-82.90M	USD	3 Qtrs
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.59B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.48B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.63B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.40B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.59B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.48B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.63B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.40B	USD	Point-in-time

Stockholders Equity 62 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquity`	$10.50B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$12.13B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$9.76B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$9.44B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$10.13B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$8.76B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$9.06B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$11.09B	USD	Point-in-time
Issuance of Common Stock for equity awards granted under long-term incentive plans	`StockIssuedDuringPeriodValueShareBasedCompensation`	$8.30M	USD	1 Quarter
Issuance of Common Stock for equity awards granted under long-term incentive plans	`StockIssuedDuringPeriodValueShareBasedCompensation`	$140.90M	USD	1 Quarter
Issuance of Common Stock for equity awards granted under long-term incentive plans	`StockIssuedDuringPeriodValueShareBasedCompensation`	$297.50M	USD	1 Quarter
Issuance of Common Stock for equity awards granted under long-term incentive plans	`StockIssuedDuringPeriodValueShareBasedCompensation`	$1.36B	USD	1 Quarter
Issuance of Common Stock for equity awards granted under long-term incentive plans	`StockIssuedDuringPeriodValueShareBasedCompensation`	$817.40M	USD	1 Quarter
Issuance of Common Stock for equity awards granted under long-term incentive plans	`StockIssuedDuringPeriodValueShareBasedCompensation`	$13.90M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$80.90M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$29.70M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$155.10M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$416.50M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$100.00K	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$10.70M	USD	1 Quarter
Issuance/distribution of Common Stock for 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$6.00M	USD	1 Quarter
Issuance/distribution of Common Stock for 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$10.50M	USD	1 Quarter
Issuance/distribution of Common Stock for 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$10.10M	USD	1 Quarter
Issuance/distribution of Common Stock for 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$11.70M	USD	1 Quarter
Issuance/distribution of Common Stock for 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$9.90M	USD	1 Quarter
Issuance/distribution of Common Stock for 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$14.60M	USD	1 Quarter
Repurchases of Common Stock (in shares)	`TreasuryStockSharesAcquired`	9.81M	shares	Point-in-time
Repurchases of Common Stock	`TreasuryStockValueAcquiredCostMethod`	$100.40M	USD	1 Quarter
Repurchases of Common Stock	`TreasuryStockValueAcquiredCostMethod`	$48.70M	USD	1 Quarter
Repurchases of Common Stock	`TreasuryStockValueAcquiredCostMethod`	$5.07B	USD	1 Quarter
Repurchases of Common Stock	`TreasuryStockValueAcquiredCostMethod`	$5.00B	USD	Point-in-time
Repurchases of Common Stock	`TreasuryStockValueAcquiredCostMethod`	$54.00M	USD	1 Quarter
Repurchases of Common Stock	`TreasuryStockValueAcquiredCostMethod`	$336.00M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$109.20M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$114.80M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$108.00M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$112.70M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$105.20M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$104.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$897.30M	USD	1 Quarter
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$2.36B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$669.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$842.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$624.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.32B	USD	3 Qtrs
Other comprehensive income (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$-4.70M	USD	1 Quarter
Other comprehensive income (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$-30.20M	USD	1 Quarter
Other comprehensive income (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$15.10M	USD	1 Quarter
Other comprehensive income (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$700.00K	USD	1 Quarter
Other comprehensive income (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$13.00M	USD	1 Quarter
Other comprehensive income (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$44.60M	USD	1 Quarter
Conversion of Class A Stock to Common Stock	`StockIssuedDuringPeriodValueConversionOfUnits`	-	USD	1 Quarter
Ending Balance	`StockholdersEquity`	$10.50B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$12.13B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$9.76B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$9.44B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$10.13B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$8.76B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$9.06B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$11.09B	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.